Oligonucleotide News and Research

RSS

Two scientists win Horwitz Prize for Rett syndrome breakthrough

Columbia University will award the 2026 Louisa Gross Horwitz Prize to Adrian Bird and Huda Zoghbi for their pioneering work on epigenetic regulation in the nervous system and its role in human neurological disease, particularly Rett syndrome.

2 Sep 2026

The role of UV-Vis in biopharma QC

UV-Vis and fluorescence support faster QC of nucleic acid and protein concentration.

From Thermo Fisher Scientific – Pharmaceutical and Biopharmaceutical Solutions 20 Aug 2026

New study identifies key pathway for delivering antisense cancer drugs

Antisense oligonucleotides (ASOs) have been proposed as a therapeutic approach to shut down the production of faulty proteins in a wide variety of diseases, including cancer.

11 Aug 2026

Blocking ZFP384 protein extends brain repair window after stroke

Blocking the activity of ZFP384 can prolong the brain’s endogenous repair functions after stroke, report researchers in a collaborative study.

13 Jul 2026

Prime and pull vaccine approach prevents genital herpes infection

Genital herpes is a lifelong infection. While available treatments can manage symptoms, they cannot cure the infection or prevent transmission.

22 Jun 2026

How antibody-drug conjugates are redefining targeted cancer therapy

Antibody-drug conjugates are rapidly expanding cancer therapies, with 19 approved globally and many more in development, but their success depends on better targets, payloads, linkers, dosing, and patient selection. The Cell review shows that next-generation ADCs could widen treatment options, but safety, resistance, tumor heterogeneity, and clinical translation remain major barriers.

19 May 2026

Antisense oligonucleotides reverse rare neurodevelopmental disorder in preclinical models

Scientists at St. Jude Children's Research Hospital have found they can reverse the effects of HNRNPH2-related neurodevelopmental disorder using antisense oligonucleotides (ASOs) in preclinical models. ASOs are short synthetic nucleic acid strands that target specific messenger RNA.

22 Apr 2026

Targeting protein fragment may improve Huntington disease treatments

Treatments that target a fragment of the mutant protein that causes Huntington's disease might be more effective than treatments, now in clinical trials, that target the whole protein but leave this fragment intact, a new study in mice suggests.

18 Mar 2026

DNA Script expands global access to on-demand DNA synthesis with distributor agreements in Latin America and East Asia

DNA Script, a pioneer in DNA synthesis providing scientists with rapid, on-demand access to high-quality DNA, today announced it has signed distribution agreements with Gencell, Bio-Medical Science Co. (BMS), and BioStream Co., expanding global access to the Company's SYNTAX® platform for decentralized, in-house and on-demand oligonucleotide production.

From DNA Script 18 Mar 2026

Alexandra Knauer receives the Pittcon Heritage Award

Entrepreneur Alexandra Knauer, managing director of lab instrument manufacturer KNAUER, is honored in the USA with the Pittcon Heritage Award 2026.

From KNAUER Wissenschaftliche Geräte GmbH 10 Mar 2026

Researchers find novel path to treat Rett syndrome

A team of researchers at Texas Children's Duncan Neurological Research Institute (NRI) and Baylor College of Medicine report in Science Translational Medicine a potential new approach to treat Rett syndrome – offering early promise for a rare neurodevelopmental disorder that currently has no cure.

5 Mar 2026

MULTI-evolve accelerates protein engineering with machine learning

The search space for protein engineering grows exponentially with complexity. A protein of just 100 amino acids has 20^100 possible variants-more combinations than atoms in the observable universe.

19 Feb 2026

Study offers hope for preventing hydrocephalus in children

Hydrocephalus is a life-threatening condition that occurs in about 1 in 1,000 newborns and is often treated with invasive surgery. Now, a new study offers hope of preventing hydrocephalus before it even occurs.

30 Jan 2026

CDD European Life Science Community Meeting

Collaborative Drug Discovery's Community Meeting brings the European technology and scientific communities together.

From Collaborative Drug Discovery, Inc. 30 Jan 2026

Novel antisense oligonucleotide shows promise against aggressive pancreatic cancer

Pancreatic ductal adenocarcinoma (PDAC) is the most lethal form of pancreas cancer. It's also the most common form of the disease.

8 Jan 2026

Aptamer Group and Alphazyme execute licensing agreement for synthetic aptamer-based enzyme modulation in hot-start PCR

Aptamer Group plc, a developer of synthetic oligonucleotide-based binding reagents for life sciences applications, and Alphazyme LLC (Alphazyme), a Maravai LifeSciences company specializing in enzymes for molecular biology, have executed a licensing agreement for a proprietary Optimer® binder developed for hot-start polymerase chain reaction (PCR) applications.

From Aptamer Group 24 Dec 2025

Tau biology expands beyond microtubules to neurodegeneration, metabolism and mental illness

An Thought Leaders Invited Review published today in Genomic Psychiatry by Dr. Peng Lei and colleagues presents a sweeping synthesis of tau protein research that fundamentally reframes our understanding of this molecule's dual identity.

16 Dec 2025

Top-five pharmaceutical company expands partnership with Aptamer for multi-target Optimer® development program

Aptamer Group plc, the developer of next-generation synthetic binders for the life sciences industry, today announced a new contract valued at up to £617,000 with a top-five pharmaceutical company.

4 Nov 2025

Study reveals how TDP-43 causes neuronal overactivity in ALS and FTD

A new Northwestern University study using patient nervous tissue and lab-grown human neurons has uncovered how a key disease protein, TDP-43, drives overactive nerve cells in the neurodegenerative diseases amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD).

31 Oct 2025

How shifting antibodies fuel aging and the new therapies aiming to slow it

This review uncovers how aging reshapes immunoglobulins, particularly IgG, IgM, and IgA, driving inflammation, cellular senescence, and tissue degeneration. By dissecting B-cell dysfunction, glycosylation changes, and Fc receptor pathways, it reveals immunoglobulins as both biomarkers and potential therapeutic targets in aging.

14 Oct 2025